Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City | Zendy

David Landman | Zendy; Ellappan Babu | Zendy; Neil V. Shah | Zendy; Paul Kelly | Zendy; Martín Bäcker | Zendy; Simona Bratu | Zendy; John Quale | Zendy

Open Access

Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City

Author(s) -

David Landman,

Ellappan Babu,

Neil V. Shah,

Paul Kelly,

Martín Bäcker,

Simona Bratu,

John Quale

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq278

Subject(s) - klebsiella pneumoniae , microbiology and biotechnology , amikacin , aminoglycoside , gentamicin , tobramycin , biology , escherichia coli , multiple drug resistance , enterobacteriaceae , efflux , antibiotics , gene , genetics

Reports of Enterobacteriaceae resistant to all commonly used antimicrobial agents, including β-lactams, fluoroquinolones and aminoglycosides, are increasing in hospitals worldwide. The activity of ACHN-490, a next-generation aminoglycoside, was examined against clinical isolates of Escherichia coli and Klebsiella pneumoniae from hospitals in New York City, an area where multidrug-resistant organisms are endemic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research